| SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface F Bertoglio, D Meier, N Langreder, S Steinke, U Rand, L Simonelli, ... Nature communications 12 (1), 1577, 2021 | 82 | 2021 |
| A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations F Bertoglio, V Fühner, M Ruschig, PA Heine, L Abassi, T Klünemann, ... Cell reports 36 (4), 2021 | 74 | 2021 |
| Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy KDR Roth, EV Wenzel, M Ruschig, S Steinke, N Langreder, PA Heine, ... Frontiers in cellular and infection microbiology 11, 697876, 2021 | 53 | 2021 |
| Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2 SK Hotop, S Reimering, A Shekhar, E Asgari, U Beutling, C Dahlke, ... Emerging microbes & infections 11 (1), 1037-1048, 2022 | 17 | 2022 |
| A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD … F Bertoglio, V Fühner, M Ruschig, PA Heine, L Abasi, T Klünemann, ... BioRxiv, 2020.12. 03.409318, 2020 | 17 | 2020 |
| ORFeome phage display reveals a major immunogenic epitope on the S2 subdomain of SARS-CoV-2 spike protein R Ballmann, SK Hotop, F Bertoglio, S Steinke, PA Heine, MZ Chaudhry, ... Viruses 14 (6), 1326, 2022 | 8 | 2022 |
| Baculovirus-Free SARS-CoV-2 virus-like particle production in insect cells for rapid neutralization assessment M Jaron, M Lehky, M Zarà, CN Zaydowicz, A Lak, R Ballmann, PA Heine, ... Viruses 14 (10), 2087, 2022 | 6 | 2022 |
| SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun 12: 1577 F Bertoglio, D Meier, N Langreder, S Steinke, U Rand, L Simonelli, ... | 5 | 2021 |
| Antibody Selection via Phage Display in Microtiter Plates S Steinke, KDR Roth, M Ruschig, N Langreder, S Polten, KT Schneider, ... Phage Display: Methods and Protocols, 247-260, 2023 | 2 | 2023 |
| Therapeutic antibodies with neutralizing activity against sars-cov-2 glycoprotein s A Frenzel, K Philipp, J Kügler, M Hust, S Dübel, D Meier, F Bertoglio, ... US Patent App. 18/000,672, 2024 | | 2024 |
| Mapping Epitopes by Phage Display S Steinke, KDR Roth, R Englick, N Langreder, R Ballmann, V Fühner, ... Phage Display: Methods and Protocols, 563-585, 2023 | | 2023 |
| Antibody Batch Cloning R Ballmann, KT Schneider, KDR Roth, S Dübel Phage Display: Methods and Protocols, 411-417, 2023 | | 2023 |
| Biomarker Discovery by ORFeome Phage Display PA Heine, R Ballmann, P Thevarajah, G Russo, GMSG Moreira, M Hust Phage Display: Methods and Protocols, 543-561, 2023 | | 2023 |
| Library Based Approaches for SARS-CoV-2 Research R Ballmann Technische Universität Carolo-Wilhelmina zu Braunschweig, 2023 | | 2023 |
| ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-Cov-2 Spike Protein (preprint) R Ballmann, SK Hotop, F Bertoglio, S Steinke, PA Heine, MZ Chaudhry, ... | | 2022 |
| SARS-CoV-2 D614 and G614 spike variants impair neuronal synapses and exhibit differential fusion ability (preprint) CY Chen, YC Chou, YP Hsueh, R da Silva Ramos, PT Felix Sr, ... | | 2020 |
